Cardiovascular And Soft Tissue Repair Patches Market Report 2026

Cardiovascular And Soft Tissue Repair Patches Market Overview

• Cardiovascular And Soft Tissue Repair Patches market size has reached to $4.85 billion in 2025 • Expected to grow to $8.09 billion in 2030 at a compound annual growth rate (CAGR) of 10.6% • Growth Driver: Increasing Prevalence Of Cardiovascular Diseases Fuels Surge In Cardiovascular And Soft Tissue Repair Patch Market • Market Trend: Adoption of Expandable Bio-Integrative Patches in Cardiovascular and Soft Tissue Repair • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cardiovascular And Soft Tissue Repair Patches Market?

Cardiovascular and soft tissue repair patches refer to artificial tissue generated in the laboratory used for the restoration of damaged body tissue made up of tissues grown in the laboratory and polymers. These are used for the replacement of damaged body parts to maintain the functioning of a body organ, provide mechanical regeneration support for damaged myocardium layers, and restore functional characteristics of injured tissue for the treatment of cardiovascular diseases. The main raw materials of cardiovascular and soft tissue repair patches are eptfe, biomaterial and tissue-engineered material, and other raw materials. The ePTFE material is used in the manufacturing of medical devices such as catheters, biocompatible services, and cardiac sutures. The ePTFE is an expanded Polytetrafluoroethylene material made up of tetrafluoroethylene polymer units composed of Teflon. The products are synthetic patches and biological patches. The applications are cardiac repair, atrial septal defect, common atrium, defects of the endocardial cushion, ventricular septal defect, tetralogy of Fallot, right ventricular outflow tract reconstruction, suture bleeding, vascular repair and reconstruction, transposition of the great vessels. The end users include hospitals, ambulatory surgical centers, and specialty clinics.

What Is The Cardiovascular And Soft Tissue Repair Patches Market Growth Forecast?

The cardiovascular and soft tissue repair patches market size is expected to see rapid growth in the next few years. It will grow to $8.09 billion in 2030 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to increasing demand for regenerative cardiovascular treatments, rising investments in tissue engineering research, expansion of advanced cardiac reconstruction procedures, growing focus on absorbable patch materials, increasing adoption of personalized repair solutions. Major trends in the forecast period include increasing adoption of biologic repair patches, rising use of tissue-engineered materials, growing focus on regenerative cardiac therapies, expansion of minimally invasive patch implantation, enhanced emphasis on biocompatibility and healing.

Global Cardiovascular And Soft Tissue Repair Patches Market Segmentation

1) By Raw Materials: ePTFE, Biomaterial and Tissue-Engineered Material, Other Raw Materials 2) By Product: Synthetic Patch, Biologic Patch 3) By Application: Cardiac Repair, Atrial Septal Defect, Ventricular Septal Defect, Tetralogy Of Fallot, Right Ventricular Outflow Tract Reconstruction, Vascular Repair And Reconstruction, Transposition Of The Great Vessels 4) By End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics Subsegments: 1) By ePTFE (Expanded Polytetrafluoroethylene): Non-Absorbable ePTFE Patches, Absorbable ePTFE Patches 2) By Biomaterial and Tissue-Engineered Material: Collagen-Based Patches, Synthetic Polymer-Based Patches, Decellularized Tissue Patches 3) By Other Raw Materials: Silicones, Hydrogel-Based Materials, Natural Materials

What Is The Driver Of The Cardiovascular And Soft Tissue Repair Patches Market?

The increasing prevalence of cardiovascular diseases is expected to propel the growth of the cardiovascular and soft tissue repair patches market going forward. Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels, including conditions such as heart attacks, strokes, and hypertension, often caused by factors like poor diet, lack of exercise, smoking, and genetics. The increasing prevalence of cardiovascular diseases is primarily driven by aging populations, unhealthy lifestyle choices, and rising rates of risk factors such as obesity, diabetes, and hypertension. Cardiovascular and soft tissue repair patches are used in cardiovascular diseases to reinforce or replace damaged heart or blood vessel tissues, helping restore structural integrity and proper function. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024 up 4.0% from 224.4 per 100,000 in 2023. Therefore, the increasing prevalence of cardiovascular disease is driving the growth of the cardiovascular and soft tissue repair patches industry.

Key Players In The Global Cardiovascular And Soft Tissue Repair Patches Market

Major companies operating in the cardiovascular and soft tissue repair patches market are B. Braun, Baxter International Inc., CorMatrix Cardiovascular Inc., CryoLife Inc., Edwards Lifesciences Corporation, LeMaitre Vascular Inc., Anteris Technologies Limited, Abbott Laboratories, Terumo Medical Corporation, Integra LifeSciences Corporation, W. L. Gore & Associates Inc., Medtronic Inc., LifeCell Corporation, ACell Inc., Tissue Regenix Group Plc, Aroa Biosurgery Ltd., LifeNet Health Inc., Cook Medical, Getinge AB, Glycar SA Pty Ltd., Biointegral Surgical Inc., Admedus Ltd., Johnson & Johnson, Stryker Corporation, Zimmer Biomet, Smith & Nephew plc, Organogenesis Inc.

Global Cardiovascular And Soft Tissue Repair Patches Market Trends and Insights

Major companies operating in the cardiovascular and soft tissue repair patches market are focusing on developing advanced expandable, bio-integrative surgical patches to meet the rising demand for long-term, biocompatible implants that can accommodate patient growth and reduce re-interventions. An expandable, bio-integrative patch is designed using a mix of bio-absorbable and non-absorbable yarns within a knitted structure, which is coated with cross-linked gelatin; after implantation, the absorbable portion gradually degrades, while the patient’s own tissue grows in to envelop the remaining non-absorbable mesh, thereby reducing foreign-body response and inflammation while allowing the patch to enlarge as the patient’s body grows. For instance, in July 2023, Teijin Limited, a Japan-based materials and healthcare company, received manufacturing and marketing approval from Japan’s Ministry of Health for SYNFOLIUM (development code OFT G1). This novel surgical patch features a knitted structure of both bio-absorbable and permanent yarns, coated in cross-linked gelatin to prevent blood leakage; over time, native tissue infiltrates and replaces the biodegradable fibers, promoting regeneration, while the remaining structure retains strength and expands to match physiological growth. Because of this design, SYNFOLIUM® can significantly lower risks associated with traditional synthetic or non-growing patches, such as calcification, stiffening, or immune reactions.

What Are Latest Mergers And Acquisitions In The Cardiovascular And Soft Tissue Repair Patches Market?

In June 2024, Stryker, a US-based medical equipment manufacturing company, acquired Artelon for an undisclosed amount. This acquisition aims to enhance its product portfolio in the field of joint preservation and soft tissue reconstruction. Artelon specializes in innovative biomaterials designed for soft tissue reinforcement and repair, particularly in sports medicine and extremities procedures. Artelon is a Georgia-based medical equipment manufacturing company.

Regional Outlook

North America was the largest region in the cardiovascular and soft tissue repair patches market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Cardiovascular And Soft Tissue Repair Patches Market?

The cardiovascular and soft tissue repair patches market consists of sales of xenogeneic patch and allogeneic patch. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.